Categories: Entertainment

Cureus Updates Terms & Conditions to Prohibit AI Use

SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ — In an era dominated by artificial intelligence, the Cureus Journal of Medical Science is taking a bold stand against the unchecked use of human-authored research by large language models (LLMs). AI companies harvest open-access content to train algorithms, they justify this practice through broad interpretations of Creative Commons licenses. Cureus says: Your ideas belong to you and no machine gets to use them without your permission.

- Advertisement -

Cureus has updated its Terms & Conditions to explicitly prohibit the use of site content by artificial intelligence systems, including:

- Advertisement -
  • Training AI or machine learning models
  • Data mining or scraping
  • Creating derivative works based on Cureus articles

“In connection with your Use of the Site Content, you must…not use the Site Content in combination with artificial intelligence…to train an algorithm, machine learning tool, or other artificial intelligence technology.”

- Advertisement -

This isn’t just a legal change — it’s a declaration of values. Cureus believes authorship is a human right, and we’re committed to preserving the originality and intellectual integrity of every article we publish.

- Advertisement -

“We’re not anti-technology. We’re pro-human. We’re not anti-progress. We’re pro-author. In an age where machines can replicate text, but not insight, Cureus remains committed to amplifying authentic scientific voices. Because real knowledge isn’t just generated– it’s discovered, tested, and told by humans.”

- Advertisement -

– Professor John Adler, MD.
(co-founder, co-editor-in-chief)

- Advertisement -

Founded to democratize medical publishing, Cureus eliminates traditional barriers like APCs and paywalls. As part of Springer Nature, Cureus continues to lead innovation in open-access publishing.

- Advertisement -

Fast facts about Cureus:

- Advertisement -
  • Over 25,000 articles published in 2024
  • 6.3 million monthly article views
  • Indexed in PubMed Central, Google Scholar, Dimensions, and more
  • No APCs; sliding-scale editing fees
  • 52% acceptance rate

Media Contact:
Cureus Editorial Office
Email: info@cureus.com
Website: www.cureus.com

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/cureus-updates-terms–conditions-to-prohibit-ai-use-302546487.html

- Advertisement -
PRNW Agency

Recent Posts

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

4 days ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

1 week ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans…

1 month ago